Literature DB >> 22542550

Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines.

Olivia Tania Hernández-Hernández1, Tania Karina González-García, Ignacio Camacho-Arroyo.   

Abstract

Astrocytomas are the most common primary brain tumors in humans. It has been reported that vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), cyclin D1 and progesterone receptor (PR) expression levels are elevated in patients with high-grade astrocytomas. Progesterone (P) regulates astrocytomas growth through its interaction with PR, which recruits coregulatory proteins such as steroid receptor coactivator-1 (SRC-1) that are required for efficient transcriptional activation. The regulation of VEGF, EGFR and cyclin D1 expression by P in human astrocytoma cells is not known. We studied the role of PR and SRC-1 in the expression of VEGF, EGFR and cyclin D1 mediated by P in human astrocytoma cell lines grade III (U373) and IV (D54). P significantly increased VEGF and EGFR mRNA expression after 12h of treatment in D54 cells that was reflected at protein level 24h after treatment. This effect was blocked by the PR antagonist, RU 486. In U373 cells cyclin D1 mRNA and protein expression was induced by P after 6 and 8h of treatment, respectively, and this effect was blocked with RU 486. Transfection with short hairpin RNA targeting coactivator SRC-1 significantly reduced VEGF expression after 24h of treatment. Collectively, our results indicate that P regulates VEGF and EGFR expression in D54 cells and cyclin D1 expression in U373 through PR, and that SRC-1 participates in the regulation of VEGF expression.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542550     DOI: 10.1016/j.jsbmb.2012.04.005

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  19 in total

1.  Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study.

Authors:  Lene Andersen; Søren Friis; Jesper Hallas; Pernille Ravn; Bjarne W Kristensen; David Gaist
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

Review 2.  Nuclear receptor coactivators: regulators of steroid action in brain and behaviour.

Authors:  M J Tetel; K D Acharya
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

3.  Communication between genomic and non-genomic signaling events coordinate steroid hormone actions.

Authors:  Sandi R Wilkenfeld; Chenchu Lin; Daniel E Frigo
Journal:  Steroids       Date:  2017-11-16       Impact factor: 2.668

4.  C/EBPβ Isoforms Expression in the Rat Brain during the Estrous Cycle.

Authors:  Valeria Hansberg-Pastor; Ana Gabriela Piña-Medina; Aliesha González-Arenas; Ignacio Camacho-Arroyo
Journal:  Int J Endocrinol       Date:  2015-04-29       Impact factor: 3.257

5.  Pericytes contribute to the disruption of the cerebral endothelial barrier via increasing VEGF expression: implications for stroke.

Authors:  Ying Bai; Xinjian Zhu; Jie Chao; Yuan Zhang; Cheng Qian; Peicheng Li; Dongfang Liu; Bing Han; Lei Zhao; Jianqiong Zhang; Shilpa Buch; Gaojun Teng; Gang Hu; Honghong Yao
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

6.  Progesterone induces the growth and infiltration of human astrocytoma cells implanted in the cerebral cortex of the rat.

Authors:  Liliana Germán-Castelán; Joaquín Manjarrez-Marmolejo; Aliesha González-Arenas; María Genoveva González-Morán; Ignacio Camacho-Arroyo
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

7.  High progesterone receptor expression in prostate cancer is associated with clinical failure.

Authors:  Thea Grindstad; Sigve Andersen; Samer Al-Saad; Tom Donnem; Yury Kiselev; Christian Nordahl Melbø-Jørgensen; Kaja Skjefstad; Lill-Tove Busund; Roy M Bremnes; Elin Richardsen
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

8.  Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex.

Authors:  Suhong Yu; Xingtian Yang; Yewei Zhu; Fangwei Xie; Yusheng Lu; Ting Yu; Cuicui Yan; Jingwei Shao; Yu Gao; Fan Mo; Guoneng Cai; Patrick J Sinko; Lee Jia
Journal:  Sci Rep       Date:  2015-01-19       Impact factor: 4.379

9.  Progesterone Receptor Together with PKCα Expression as Prognostic Factors for Astrocytomas Malignancy.

Authors:  Denisse Arcos-Montoya; Talia Wegman-Ostrosky; Sonia Mejía-Pérez; Marisol De la Fuente-Granada; Ignacio Camacho-Arroyo; Alejandro García-Carrancá; Marco A Velasco-Velázquez; Joaquín Manjarrez-Marmolejo; Aliesha González-Arenas
Journal:  Onco Targets Ther       Date:  2021-06-16       Impact factor: 4.147

10.  Mifepristone improves chemo-radiation response in glioblastoma xenografts.

Authors:  Monserrat Llaguno-Munive; Luis Alberto Medina; Rafael Jurado; Mario Romero-Piña; Patricia Garcia-Lopez
Journal:  Cancer Cell Int       Date:  2013-03-25       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.